RETRACTED: High-mobility group protein B1 (HMGB1) is a novel biomarker for human ovarian cancer

This article has been retracted: please see Elsevier Policy on Article Withdrawal (http://www.elsevier.com/locate/withdrawalpolicy).

This article has been retracted at the request of the Editor-in-Chief and the authors.

The Editors of Gynecologic Oncology were recently alerted to the fact that the article duplicates data from a paper previously published in the Journal of Cellular Physiology (Chen J, Liu X, Zhang J, Zhao Y. Targeting HMGB1 inhibits ovarian cancer growth and metastasis by lentivirus-mediated RNA interference. J Cell Physiol. 2012; 227: 3629-38, http://dx.doi.org/10.1002/jcp.24069).

The authors of the article have asked the Editor-in-Chief and the Publisher to communicate the following information to readers:

• While the date of submission of the Journal of Cellular Physiology article (14^th September 2011) is earlier than the date of submission of the Gynecologic Oncology article (13^th November 2011), most of the text in the Journal of Cellular Physiology article was copied, and subsequently modified, from the Gynecologic Oncology article, which was primarily written by Dr Chunyu Wang.

• The three authors of the Gynecologic Oncology article who are not listed as authors on the Journal of Cellular Physiology article, Drs Bo Xi, Yang Yu and Chunyu Wang, were not aware of the dual submission and subsequent dual publication until contacted by the Editors of Gynecologic Oncology.

• Dr Jie Chen, first author on both articles, takes full responsibility for the dual submission and apologises to the readership of Gynecologic Oncology. Other co-authors should be exempted from all responsibilities.